DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.

@article{Walter2012DNAMP,
  title={DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.},
  author={Kim Walter and Thomas M. Holcomb and Tom Januario and Pan Du and Marie Evangelista and Nithya Kartha and Leonardo A. Iniguez and R Ollero Soriano and Ling Y. Huw and Howard Stern and Zora Modrusan and Somasekar Seshagiri and Garret M. Hampton and Lukas C. Amler and Richard Bourgon and Robert L. Yauch and David S. Shames},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 8},
  pages={2360-73}
}
PURPOSE Non-small cell lung cancers (NSCLC) comprise multiple distinct biologic groups with different prognoses. For example, patients with epithelial-like tumors have a better prognosis and exhibit greater sensitivity to inhibitors of the epidermal growth factor receptor (EGFR) pathway than patients with mesenchymal-like tumors. Here, we test the hypothesis that epithelial-like NSCLCs can be distinguished from mesenchymal-like NSCLCs on the basis of global DNA methylation patterns… CONTINUE READING